Plus Therapeutics

About:

Plus Therapeutics is a clinical-stage pharmaceutical company that develops targeted therapies to treat cancer and other serious diseases.

Website: http://www.plustherapeutics.com

Twitter/X: plustxinc

Top Investors: U.S. Department of Defense, Silicon Valley Bank, Cancer Prevention and Research Institute of Texas, Oxford Finance LLC, GE Capital

Description:

Plus Therapeutics is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. It is a global, public company engaged in developing and commercializing stem and regenerative cell therapies for treating cardiovascular disease, reconstructive surgery, and other serious, chronic, and life-threatening conditions. The company's research and development efforts are developing novel formulations and delivery methods for existing drugs to improve their efficacy and reduce side effects. Plus Therapeutics utilizes its proprietary nanotechnology platform to enhance the therapeutic potential of drugs, allowing for targeted delivery to tumors while minimizing damage to healthy tissues. Their pipeline includes potential treatments for various types of cancer, including brain cancer and pancreatic cancer. Plus Therapeutics' pipeline of candidate drug products includes their lead drug product candidates, RNL and DocePLUS, which are being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.